Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays

Ann Lab Med. 2024 May 1;44(3):195-209. doi: 10.3343/alm.2023.0389. Epub 2024 Jan 15.ABSTRACTCirculating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an in-depth exploration of the clinical implementation of ctDNA assays. Notably, we examined existing evidence related to pre-analytical procedures, analytical components in current technologies, and result interpretation and reporting processes. The primary objective of this guidelines is to provide recommendations for the clinical utilization of ctDNA assays.PMID:38221747 | PMC:PMC10813828 | DOI:10.3343/alm.2023.0389

Source: Annals of Laboratory Medicine - January 15, 2024 Category: Laboratory Medicine Authors: Jee-Soo Lee Eun Hye Cho Boram Kim Jinyoung Hong Young-Gon Kim Yoonjung Kim Ja-Hyun Jang Seung-Tae Lee Sun-Young Kong Woochang Lee Saeam Shin Eun Young Song Clinical Practice Guidelines Committee of the Korean Society for Laboratory Medicine Source Type: research